These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37403871)

  • 21. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020.
    Chobufo MD; Regner SR; Zeb I; Lacoste JL; Virani SS; Balla S
    Eur J Prev Cardiol; 2022 Oct; 29(14):1830-1838. PubMed ID: 35653373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease.
    Muntner P; Orroth KK; Mues KE; Exter J; Shannon ED; Zaha R; Rosenson RS; Jackson EA
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):475-481. PubMed ID: 33661432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Incident Atherosclerotic Cardiovascular DiseaseEvents by Achieved Atherogenic Lipid Levels Among62,428 Statin-Treated Individuals With Diabetes Mellitus.
    Rana JS; Liu JY; Moffet HH; Boklage SH; Khan I; Karter AJ
    Am J Cardiol; 2018 Sep; 122(5):762-767. PubMed ID: 30057224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
    Maddox TM; Borden WB; Tang F; Virani SS; Oetgen WJ; Mullen JB; Chan PS; Casale PN; Douglas PS; Masoudi FA; Farmer SA; Rumsfeld JS
    J Am Coll Cardiol; 2014 Dec; 64(21):2183-92. PubMed ID: 25447259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?
    Cesena FHY; Laurinavicius AG; Valente VA; Conceição RD; Santos RD; Bittencourt MS
    Clin Cardiol; 2018 Mar; 41(3):333-338. PubMed ID: 29574925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol.
    Harrison TN; Scott RD; Cheetham TC; Chang SC; Hsu JY; Wei R; Ling Grant DS; Boklage SH; Romo-LeTourneau V; Reynolds K
    Cardiovasc Drugs Ther; 2018 Aug; 32(4):397-404. PubMed ID: 30062465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk.
    Cesena FHY; Laurinavicius AG; Valente VA; Conceição RD; Santos RD; Bittencourt MS
    Arq Bras Cardiol; 2017 Jun; 108(6):518-525. PubMed ID: 28699975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-Related Associations of Low-Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Cohort Study.
    Jung HN; Kim MJ; Kim HS; Lee WJ; Min SH; Kim YJ; Jung CH
    J Am Heart Assoc; 2022 May; 11(9):e024637. PubMed ID: 35492003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remnant cholesterol and atherosclerotic disease in high cardiovascular risk patients. Beyond LDL cholesterol and hypolipidemic treatment.
    Delialis D; Georgiopoulos G; Aivalioti E; Mavraganis G; Dimopoulou AM; Sianis A; Aggelidakis L; Patras R; Petropoulos I; Ioannou S; Syrigou R; Chatzidou S; Kanakakis I; Stellos K; Stamatelopoulos K
    Hellenic J Cardiol; 2022; 66():26-31. PubMed ID: 35667617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease.
    Zhao Y; Xiang P; Coll B; López JAG; Wong ND
    J Diabetes Complications; 2021 Mar; 35(3):107767. PubMed ID: 33168394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
    Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
    Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
    Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
    JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
    Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS
    JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta.
    Chen G; Farris MS; Cowling T; Colgan SM; Xiang P; Pericleous L; Rogoza RM; Tai MH; Anderson T
    Can J Cardiol; 2019 Jul; 35(7):884-891. PubMed ID: 31292087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.
    Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new pooled cohort equations risk calculator.
    Preiss D; Kristensen SL
    Can J Cardiol; 2015 May; 31(5):613-9. PubMed ID: 25843167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.